At a glance
What is it—and why does it matter?
Hexarelin is categorized as a growth hormone secretagogue (GHS), i.e., a peptide used with the intent to stimulate growth hormone release, and it is noted as commonly encountered in both clinical settings and online self-administration protocols.
Sources for this introduction: [1]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
Hexarelin is categorized as a growth hormone secretagogue (GHS), i.e., a peptide used with the intent to stimulate growth hormone release, and it is noted as commonly encountered in both clinical settings and online self-administration protocols.
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagogues (GHS; e.g., growth hormone-releasing peptide-2 (GHRP-2), growth hormone-releasing peptide-6 (GHRP-6), hexarelin, ipamorelin), the growth hormone (GH) fragment - AOD9604 (hGH 176-191), and insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)).”
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. · Abstract
pubmed:42395176:9df538e1edba:9df538e1edba
How does it work?
Target, response, and disposition.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
What has been studied?
What the evidence says.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
- 9 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (6), assurance_score_below_0.72 (2), current_regulatory_source_required (2), extraction_ambiguity (9), high_risk_requires_regulatory_or_two_independent_sources (2), no_direct_support (8)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. ↗
pubmed · published 2026-01-01 · retrieved 2026-08-17T23:10:15Z
Publication history and provenance
Version 3 · Automated assessment · 2026-08-27T11:48:55Z
e6787c1b8efb4310098006a5a29a1ddc81c8de8947b150f5c9e9ef6e64746ee5